JP2006523681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523681A5 JP2006523681A5 JP2006507373A JP2006507373A JP2006523681A5 JP 2006523681 A5 JP2006523681 A5 JP 2006523681A5 JP 2006507373 A JP2006507373 A JP 2006507373A JP 2006507373 A JP2006507373 A JP 2006507373A JP 2006523681 A5 JP2006523681 A5 JP 2006523681A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- substituted
- heteroaryl
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002947 alkylene group Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000003107 substituted aryl group Chemical group 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000005275 alkylenearyl group Chemical group 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229940126289 DNA-PK inhibitor Drugs 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- -1 mercapto, sulfonyl Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 230000003389 potentiating effect Effects 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 2
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MMNTZXRQPVRSSO-UHFFFAOYSA-N sulfamoylformic acid Chemical compound NS(=O)(=O)C(O)=O MMNTZXRQPVRSSO-UHFFFAOYSA-N 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- PGZHNNQJLYEKLU-UHFFFAOYSA-N (1-hydroxy-9-oxo-10h-acridin-3-yl) trifluoromethanesulfonate Chemical compound N1C2=CC=CC=C2C(=O)C2=C1C=C(OS(=O)(=O)C(F)(F)F)C=C2O PGZHNNQJLYEKLU-UHFFFAOYSA-N 0.000 claims 1
- NNVAYMMKUNCJKX-UHFFFAOYSA-N 1-hydroxy-3-morpholin-4-yl-10h-acridin-9-one Chemical compound C=1C=2NC3=CC=CC=C3C(=O)C=2C(O)=CC=1N1CCOCC1 NNVAYMMKUNCJKX-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 230000003007 single stranded DNA break Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45699903P | 2003-03-24 | 2003-03-24 | |
| PCT/US2004/008459 WO2004085418A2 (en) | 2003-03-24 | 2004-03-19 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523681A JP2006523681A (ja) | 2006-10-19 |
| JP2006523681A5 true JP2006523681A5 (enExample) | 2009-07-23 |
Family
ID=33098184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507373A Pending JP2006523681A (ja) | 2003-03-24 | 2004-03-19 | Ｄｎａ−ｐｋ阻害剤としてのキサントン、チオキサントンおよびアクリジノン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8404681B2 (enExample) |
| EP (1) | EP1660473A2 (enExample) |
| JP (1) | JP2006523681A (enExample) |
| AU (1) | AU2004223866A1 (enExample) |
| CA (1) | CA2523178C (enExample) |
| WO (1) | WO2004085418A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1330444B1 (en) | 2000-11-01 | 2011-03-23 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic compounds and process for making them |
| JP5317472B2 (ja) | 2004-03-15 | 2013-10-16 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｓｎｓ−５９５、及びその使用方法 |
| PL1865924T3 (pl) * | 2005-03-31 | 2016-06-30 | Lidds Ab | Sposób leczenia chorób gruczołu krokowego oparty na miejscowym dostarczaniu substancji czynnych |
| US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| CA2654876A1 (en) | 2006-06-12 | 2007-12-21 | Sunesis Pharmaceuticals, Inc. | 1-8-naphthyridine compounds for the treatment of cancer |
| AU2008317400B2 (en) | 2007-10-22 | 2014-10-02 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy |
| LT2280720T (lt) | 2008-03-27 | 2019-07-25 | Purdue Research Foundation | Kolageną surišantys sintetiniai peptidoglikanai, jų paruošimas ir naudojimo būdai |
| EP2585112B1 (en) * | 2010-06-23 | 2019-05-15 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans for use in vascular intervention |
| TWI414520B (zh) * | 2010-10-06 | 2013-11-11 | Nat Defense Medical Ct | 噻噸酮衍生物 |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| SG195114A1 (en) | 2011-05-24 | 2013-12-30 | Purdue Research Foundation | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use |
| RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP2970509B1 (en) | 2013-03-15 | 2020-05-13 | Purdue Research Foundation | Extracellular matrix-binding synthetic peptidoglycans |
| EP3052131B1 (en) | 2013-10-01 | 2018-12-05 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
| SI3424920T1 (sl) | 2013-10-17 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk |
| US10772931B2 (en) | 2014-04-25 | 2020-09-15 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
| WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
| EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
| CN104610276B (zh) * | 2014-11-06 | 2016-08-17 | 浙江工业大学 | 苯并[k,l]噻吨-3,4-二甲酸酐类衍生物-尿苷偶联物及其制备方法和应用 |
| EP3265063A4 (en) | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| CN108135863B (zh) * | 2015-04-27 | 2021-07-27 | 特拉维夫医疗中心医学研究基础设施和保健服务基金会 | 用于治疗炎性和过度增殖性病况的egr1靶向分子 |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| WO2017202798A1 (en) | 2016-05-26 | 2017-11-30 | F. Hoffmann-La Roche Ag | Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
| WO2018183868A1 (en) * | 2017-03-31 | 2018-10-04 | Bioventures, Llc | Inhibitors of dna pk and uses thereof |
| AU2018298224B2 (en) | 2017-07-07 | 2024-08-15 | Symic Ip, Llc | Synthetic bioconjugates |
| US12121524B2 (en) | 2018-01-17 | 2024-10-22 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| CN111770921B (zh) | 2018-01-17 | 2024-03-22 | 沃泰克斯药物股份有限公司 | 用于提高基因组编辑效率的喹喔啉酮化合物，组合物，方法和试剂盒 |
| ES2980444T3 (es) | 2018-01-17 | 2024-10-01 | Vertex Pharma | Inhibidores de ADN-PK |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| CN109369599B (zh) * | 2018-11-15 | 2023-03-24 | 广州医科大学 | 一种呫吨酮类化合物及其制备方法和应用 |
| WO2020180845A1 (en) * | 2019-03-04 | 2020-09-10 | University Of Washington | Methods for treating autoimmune or autoinflammatory disease |
| CN118388410B (zh) * | 2024-04-23 | 2025-07-18 | 仁合益康集团有限公司 | 一种吗啉硝唑的合成方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE630639A (enExample) | 1962-04-12 | |||
| FR8298M (enExample) | 1967-07-20 | 1970-11-16 | ||
| US3835158A (en) * | 1972-05-17 | 1974-09-10 | Syntex Inc | Heterocyclic substituted xanthone carboxylic acid compounds |
| JPS5138245B2 (enExample) | 1973-05-22 | 1976-10-20 | ||
| US3904631A (en) | 1973-05-29 | 1975-09-09 | Parke Davis & Co | Novel thioxanthenone compounds and means of producing the same |
| US4003699A (en) | 1974-11-22 | 1977-01-18 | Henkel & Cie G.M.B.H. | Oxidation hair dyes based upon tetraaminopyrimidine developers |
| DE2807761A1 (de) | 1978-02-23 | 1979-08-30 | Basf Ag | Cumarinderivate |
| DE2922488A1 (de) | 1979-06-01 | 1980-12-11 | Thiemann Chem Pharm Fab | 2-hydroxy-4-methyl-benzolverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| JPS578845A (en) | 1980-06-18 | 1982-01-18 | Fujitsu Ltd | Indeterminate processing control system |
| DE3141970A1 (de) | 1981-10-22 | 1983-05-05 | Vsesojuznyj naučno-issledovatel'skij institut lekarstvennych rastenij, Vilar, Moskovskaja oblast' | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen |
| US4436732A (en) * | 1981-10-26 | 1984-03-13 | Vichkanova Serafima A | Medicated compound for treating diseases infected by virus of the herpes group |
| EP0082109A3 (de) | 1981-10-28 | 1985-04-17 | Ciba-Geigy Ag | Substituierte 2-Hydroxy-phenylessigsäuren und Derivate davon |
| US4426380A (en) | 1981-10-28 | 1984-01-17 | Ciba-Geigy Corporation | Benzofuran-2-ones and pharmaceutical compositions |
| US4539412A (en) * | 1982-07-08 | 1985-09-03 | Rensselaer Polytechnic Institute | 7-Hydroxylucanthone, 7-hydroxhycanthone and their analogs |
| GB2128993B (en) | 1982-10-08 | 1986-01-15 | Ciba Geigy Ag | Benzofurans |
| EP0107620A1 (de) | 1982-10-13 | 1984-05-02 | Ciba-Geigy Ag | Phenol-Derivate |
| DE3800577A1 (de) | 1988-01-12 | 1989-07-20 | Basf Ag | 3-(4-amino-2-hydroxyphenyl)-1-oxo-isoindolenine, verfahren zu deren herstellung und deren verseifung zu 2-(4-amino-2-hydroxybenzoyl)-benzoesaeuren |
| EP0342665A3 (en) | 1988-05-20 | 1990-08-16 | Takeda Chemical Industries, Ltd. | Physiologically active substance tan-931, its derivatives, their production and use |
| AU5831090A (en) | 1989-05-25 | 1990-12-18 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for inhibiting tumor cell growth |
| GB9018044D0 (en) * | 1990-08-16 | 1990-10-03 | Ici Plc | Tricyclic heterocyclic derivatives |
| JPH06506202A (ja) | 1991-03-22 | 1994-07-14 | ゼノバ リミテッド | 医薬用キサントン誘導体 |
| WO1992020666A1 (fr) | 1991-05-24 | 1992-11-26 | Taiho Pharmaceutical Company, Limited | Derive de benzothiadiazine |
| US5262549A (en) | 1991-05-30 | 1993-11-16 | Polaroid Corporation | Benzpyrylium dyes, and processes for their preparation and use |
| JPH04368379A (ja) * | 1991-06-13 | 1992-12-21 | Natl Sci Council | キサントン誘導体又はそのエステルを有効成分とする血栓予防治療剤 |
| WO1995020652A1 (de) | 1994-01-28 | 1995-08-03 | Medigene Gmbh | Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens |
| DE4424712A1 (de) | 1994-07-13 | 1996-01-18 | Basf Ag | Verwendung von Benzaldehyden zum Markieren von Kohlenwasserstoffen |
| PL315636A1 (en) | 1994-11-25 | 1996-11-25 | Rocher Yves Biolog Vegetale | Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives |
| DE19501303A1 (de) | 1995-01-18 | 1996-07-25 | Henkel Kgaa | Arylketone zum Färben keratinhaltiger Fasern |
| EP1304322A3 (en) | 1995-08-22 | 2003-11-19 | Japan Tobacco Inc. | Carboxylic acid compound and use thereof |
| WO1997031891A1 (en) | 1996-03-01 | 1997-09-04 | Merck & Co., Inc. | Process for regioselective substitution of trifluorobenzoate or trifluorobenzonitrile |
| JPH09316440A (ja) * | 1996-05-27 | 1997-12-09 | Toyo Ink Mfg Co Ltd | 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子 |
| CA2236867A1 (en) | 1996-09-27 | 1998-04-02 | Icos Corporation | Method to identify compounds for disrupting protein/protein interactions |
| GB2326410A (en) | 1997-06-18 | 1998-12-23 | Merck & Co Inc | Tocolytic Oxytocin Receptor Antagonists |
| JPH11106371A (ja) | 1997-07-04 | 1999-04-20 | Nisshin Flour Milling Co Ltd | アシルヒドラゾン誘導体 |
| SE9703377D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| JP4531149B2 (ja) * | 1997-10-17 | 2010-08-25 | 富山化学工業株式会社 | 含窒素三・四環式化合物およびそれを含有する抗ウイルス剤 |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| WO1999039247A1 (en) | 1998-01-30 | 1999-08-05 | First Chemical Corporation | Photopolymerization compositions including maleimides and processes for using the same |
| EP1090146B1 (en) | 1998-06-30 | 2007-05-23 | Sloan-Kettering Institute For Cancer Research | Uses of dna-pk |
| AU6055099A (en) | 1998-09-21 | 2000-04-10 | Fox Chase Cancer Center | Assays and novel cellular targets for therapeutic agents to treat retroviral infection |
| BR9914123B1 (pt) | 1998-09-28 | 2010-11-30 | fotoiniciadores e aplicações para os mesmos. | |
| GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
| US6535593B1 (en) | 2000-02-28 | 2003-03-18 | Simplified Development Corp. | System and method for billing communications services provisioned on demand in converging telecommunications network |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2003055479A1 (en) | 2001-12-21 | 2003-07-10 | Consejo Superior De Investigaciones Cientificas | Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3 |
-
2004
- 2004-03-19 WO PCT/US2004/008459 patent/WO2004085418A2/en not_active Ceased
- 2004-03-19 AU AU2004223866A patent/AU2004223866A1/en not_active Abandoned
- 2004-03-19 CA CA2523178A patent/CA2523178C/en not_active Expired - Fee Related
- 2004-03-19 EP EP04757891A patent/EP1660473A2/en not_active Withdrawn
- 2004-03-19 US US10/550,978 patent/US8404681B2/en not_active Expired - Fee Related
- 2004-03-19 JP JP2006507373A patent/JP2006523681A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523681A5 (enExample) | ||
| CA2698075C (en) | Antiviral drugs for treatment of arenavirus infection | |
| AU723658B2 (en) | Reversible cysteine protease inhibitors | |
| JP2013513596A5 (enExample) | ||
| EP3119781B1 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| US8492434B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| CN109336819B (zh) | 二羧酸双酰胺衍生物、其用途和基于其的药物组合物 | |
| EP3426633A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| JP2017507122A5 (enExample) | ||
| CA2458035A1 (en) | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | |
| JP2017521364A5 (enExample) | ||
| SK61496A3 (en) | Prodrugs of an inhibitor of hiv protease and pharmaceutical agents containing them | |
| RU2005135927A (ru) | Пятичленное гетероциклическое производное | |
| ES2727531T3 (es) | Antineoplásico que comprende un compuesto de aminoacetonitrilo como ingrediente activo | |
| AU2016224395A1 (en) | Anti cancer agent comprising aminoacetonitrile compound as active ingredient | |
| AU2006241774A1 (en) | Therapeutic agent for chronic obstructive pulmonary disease | |
| CN111801325A (zh) | 作为Wnt信号转导通路的抑制剂的吡唑衍生物 | |
| JP6643764B2 (ja) | 抗がん剤 | |
| HK40002912B (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon | |
| HK40002912A (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon | |
| HK40002625B (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon | |
| HK40002625A (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon | |
| HK40012042A (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon | |
| HK40012042B (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon |